Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma.

ABSTRACT: Although the 5-year survival rates for sarcoma patients have improved, the proportion of patients relapsing after first-line treatment remains high, and the survival of patients with metastatic disease is dismal. Moreover, the extensive molecular heterogeneity of the multiple different sarcoma subtypes poses a substantial challenge to developing more personalized treatment strategies. From the IHC staining of a large set of 625 human soft-tissue sarcomas, we demonstrate strong tumor cell staining of the Endo180 (MRC2) receptor in a high proportion of samples, findings echoed in gene-expression data sets showing a significantly increased expression in both soft-tissue and bone sarcomas compared with normal tissue. Endo180 is a constitutively recycling transmembrane receptor and therefore an

SUBMITTER: Evans RJ 

PROVIDER: S-EPMC9890142 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature